twitter test

Article

Can circulating tumor DNA predict relapse in breast cancer?

- Dr. Muin Khoury (@DrKhouryCDC) August 30, 2015

Cool technology. Not quite ready for primetime but soon. Blood test could predict breast cancer relapse @cbsnews

- Hal Burstein, MD (@DrHBurstein) August 27, 2015

MT @NEJM: Daratumumab elicited impressive responses in pretreated myeloma pts. #mmsm

- Michael Fisch (@fischmd) August 27, 2015

Daratumumab is safe and has encouraging activity in patients with heavily pretreated and refractory myeloma

- Muzaffar Qazilbash (@Transplant_Doc) August 26, 2015

Recent Videos
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
Related Content
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer

15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer

Diana Jaber;Natalie K Heater;Surbhi Warrior;Janice Lu, MD, PhD
July 3rd 2025
Article

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS
July 3rd 2025
Podcast

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.

Investigators will present detailed results from the phase 3 FORTITUDE-101 trial at a future medical meeting.

Bemarituzumab Regimen Improves Survival in FGFR2b+ Gastric/GEJ Cancer

Russ Conroy
July 3rd 2025
Article

Investigators will present detailed results from the phase 3 FORTITUDE-101 trial at a future medical meeting.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

In those being screened for hereditary breast and ovarian cancer syndrome, use of a video tool improved the duration of physician-led genetic counseling.

Video-Based Genetic Counseling Improves Comprehension in HBOC

Tim Cortese
July 3rd 2025
Article

In those being screened for hereditary breast and ovarian cancer syndrome, use of a video tool improved the duration of physician-led genetic counseling.

Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.

Sunvozertinib Earns FDA Accelerated Approval in EGFR Exon 20+ NSCLC

Russ Conroy
July 2nd 2025
Article

Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.